MIAMI--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced financial results for the three-month and six-month periods ended June 30, 2007. Robert C. Strauss, Noven’s President, CEO & Chairman, said: “Our transdermal products business had a very good quarter and an outstanding first half, led by increased revenues from Daytrana™, improved gross margins, and a solid performance by our Novogyne joint venture due to increased sales of Vivelle-Dot®, our market leading estrogen patch. In fact, quarterly total prescriptions for Vivelle-Dot® were the highest in the product’s history.”
